CHICAGO – The U.S. Food and Drug Administration has approved Abbott’s FreeStyle Libre 14-day continuous glucose monitoring system. In the U.S., people with diabetes can wear the sensor up to 14 days with high accuracy. “People with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition,” said Jared Watkin, senior vice president, Abbott Diabetes Care, in a statement. The CGM system provides users with real-time glucose results, an eight-hour historical trend and an arrow showing the direction their glucose is going. Data from FreeStyle Libre can be shared with doctors and health care providers.
You are here: / / Abbott’s FreeStyle Libre 14-day CGM receives FDA approval